Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Galera Therapeutics, Inc. - Common Stock
(NQ:
GRTX
)
0.1450
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Galera Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Expert Ratings for Galera Therapeutics
↗
August 29, 2023
Via
Benzinga
Citigroup Maintains Neutral Rating for Galera Therapeutics: Here's What You Need To Know
↗
August 29, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2023
↗
August 16, 2023
Via
Benzinga
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
August 14, 2023
From
Galera Therapeutics
Via
GlobeNewswire
Analyst Ratings for Galera Therapeutics
↗
March 22, 2023
Via
Benzinga
Where Galera Therapeutics Stands With Analysts
↗
March 22, 2023
Via
Benzinga
Gold Edges Lower; Alibaba Posts Upbeat Results
↗
August 10, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 150 points on Thursday. The Dow traded up 0.44% to 35,277.94 while the NASDAQ rose 0.29% to 13,761.56. The S&P...
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
August 10, 2023
Via
Benzinga
Crude Oil Down 1%; Disney Profit Tops Expectations
↗
August 10, 2023
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Thursday. The Dow traded up 0.78% to 35,396.50 while the NASDAQ rose 0.84% to 13,837.91. The...
Via
Benzinga
Topics
Stocks
Disney Explores Strategic Shift Away from Traditional TV, FTX Management & Creditors Clash, Alibaba's Q1 Earnings: Today's Top Stories
↗
August 10, 2023
Financial Times
Via
Benzinga
Why Krispy Kreme Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
August 10, 2023
Gainers Edible Garden AG Incorporated (NASDAQ: EDBL) shares jumped 58% to $1.88 after the company reported better-than-expected second-quarter financial results.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
↗
August 10, 2023
Via
Benzinga
Dow Jumps Over 300 Points; US Inflation Rate Rises To 3.2%
↗
August 10, 2023
U.S. stocks traded higher this morning, following the release of inflation data on Thursday. Following the market opening Thursday, the Dow traded up 0.95% to 35,456.19 while the NASDAQ rose 1.03% to...
Via
Benzinga
Topics
Economy
Stocks
What Is Going on With Applied UV (AUVI) Stock Today?
↗
August 10, 2023
Applied UV (AUVI) stock is on the move Thursday as investors react to the disinfectant company getting $4 million in orders.
Via
InvestorPlace
Why Is Galera Therapeutics Stock Sinking Today?
↗
August 10, 2023
The FDA issued a Complete Response Letter (CRL) to Galera Therapeutics Inc's (NASDAQ: GRTX) New Drug Application (NDA) for avasopasem manganese (avasopasem) for radiotherapy-induced severe oral...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
August 10, 2023
Via
Benzinga
Why Is Amyris (AMRS) Stock Down 67% Today?
↗
August 10, 2023
Amyris (AMRS) stock is falling on Thursday after the company filed for Chapter 11 bankruptcy protection to facilitate a restructuring.
Via
InvestorPlace
Topics
Bankruptcy
Why Is Galera Therapeutics (GRTX) Stock Down 83% Today?
↗
August 10, 2023
Galera Therapeutics (GRTX) stock is falling hard on Thursday following a drug rejection by the FDA and plans to cut its workforce!
Via
InvestorPlace
Why AppLovin Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket
↗
August 10, 2023
Gainers PHAXIAM Therapeutics S.A. (NASDAQ: PHXM) shares surged 46.7% to $0.64 in pre-market trading after gaining 6% on Wednesday.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
↗
August 10, 2023
We're starting off the day with a breakdown of the biggest pre-market stock movers traders should watch on Thursday morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
August 09, 2023
Via
Benzinga
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese
August 09, 2023
From
Galera Therapeutics
Via
GlobeNewswire
Why Hims & Hers Health Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
↗
August 08, 2023
Gainers Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) shares surged 83.5% to $0.1648 in pre-market trading after falling over 25% on Monday. The company recently announced its plans to reduce the...
Via
Benzinga
Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting
June 05, 2023
From
Galera Therapeutics
Via
GlobeNewswire
Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer
May 18, 2023
Rucosopasem in clinical development to augment the anti-cancer efficacy of stereotactic body radiation therapy
From
Galera Therapeutics
Via
GlobeNewswire
Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates
May 11, 2023
From
Galera Therapeutics
Via
GlobeNewswire
Galera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 04, 2023
From
Galera Therapeutics
Via
GlobeNewswire
Galera Expands Commercial Leadership Team
May 01, 2023
From
Galera Therapeutics
Via
GlobeNewswire
Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 26, 2023
From
Galera Therapeutics
Via
GlobeNewswire
Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology
March 10, 2023
From
Galera Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.